In the United States, among patients with diabetes, 15 percent develop a foot ulcer, and 12 to 24 percent of individuals with a foot ulcer require amputation. With funding (1U01DK119099-01) from the National Institutes of Health, the Center for Regenerative Medicine and Engineering at Indiana University School of Medicine is able to treat diabetic foot ulcer with leading expertise.
The center is equipped with an interdisciplinary research and education program that delivers cutting-edge innovation that leads to the development of a Clinical Research Unit (CRU). The Center for Regenerative Medicine and Engineering is the major participant in this multi-site research consortium, focused on propelling new scientific discoveries to be expeditiously translated to better care for patients with diabetic foot ulcers.
The center is focused on providing wound-healing expertise and wound care of patient populations with diabetic foot ulcers. Using an efficient clinical and scientific infrastructure, the center is developing evidentiary criteria for qualifying/validating the targeted diabetic foot ulcer biomarker. Research faculty are developing and implementing novel strategies to monitor and address the confounding factors relevant to biomarker study outcomes. The center will establish Clinical Research Unit administration and achieve Diabetic Foot Consortium (DFC) readiness.